Vasoactive intestinal peptide increases vascular endothelial growth factor expression and neuroendocrine differentiation in human prostate cancer LNCaP cells

Regulatory Peptides

Volumn 119, Issue 1-2, 2004, Pages 69-75

  Collado, Beatriz ^a   Gutiérrez Cañas, Irene ^a   Rodríguez Henche, Nieves ^a   Prieto, Juan C ^a   Carmena, María J ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

Angiogenesis; PACAP; Prostate cancer; VEGF expression; VIP

Indexed keywords

CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; VASCULOTROPIN; VASOACTIVE INTESTINAL POLYPEPTIDE;

ARTICLE; CANCER CELL; CELL DIFFERENTIATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MALE; NEUROENDOCRINOLOGY; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CELL LINE, TUMOR; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MALE; MAP KINASE KINASE 1; MAP KINASE KINASE 2; NEOVASCULARIZATION, PATHOLOGIC; NEUROSECRETORY SYSTEMS; PROSTATIC NEOPLASMS; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; RNA, MESSENGER; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASOACTIVE INTESTINAL PEPTIDE;

EID: 1842734670     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2004.01.013     Document Type: Article

References (37)

1. Fahrenkrug J., Said S.I. VIP, PACAP, glucagon, and related peptides. 2000;Annals of the New York Academy of Sciences, New York.
2. Laburthe M., Couvineau A. Molecular pharmacology and structure of PACAP receptors for VIP and PACAP. Regul. Pept. 108:2002;165-173.
3. Deavall D.G., Raychowdhury R., Dockray G.J., Dimaline R. Control of CCK gene transcription by PACAP in STC-1 cells. Am. J. Physiol. Gastrointest. Liver Physiol. 279:2000;G605-G612.
4. González-Robayna I.J., Falender A.E., Ochsner S., Firestone G.L., Richards J.S. Follicle-stimulating hormone (FSH) stimulates phosphorylation and activation of protein kinase B (PKB/Akt) and serum and glucocorticoid-induced kinase (Sgk): evidence for A kinase-independent signaling by FSH in granulosa cells. Mol. Endocrinol. 14:2000;1283-1300.
5. Richards J. New signalling pathways for hormones and cyclic adenosine 3′,5′-monophosphate action in endocrine cells. Mol. Endocrinol. 15:2002;209-218.
6. Cantley L.C. The phosphoinositide 3-kinase pathway. Science. 296:2002;1655-1657.
7. Stork P.J.S., Schmitt J.M. Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol. 12:2002;258-266.
8. Abrahamsson P. Neuroendocrine differentiation in prostatic carcinoma. Prostate. 39:1999;135-148.
9. Schamhart D.H., Kurth K.H. Role of proteoglycans in cell adhesion of prostate cancer cells: from review to experiment. Urol. Res. 25:1997;S89-S96.
10. Brawer M.K., Deering R.E., Brown M., Preston S.D., Bigler S.A. Predictors of pathological stage in prostatic carcinoma. Cancer. 73:1994;678-687.
11. Liekens S., De Clerck E., Neyts J. Angiogenesis: regulators and clinical applications. Biochem. Pharmacol. 61:2001;253-270.
12. Cross M.J., Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol. Sci. 22:2001;201-207.
13. Ferrer F.A., Miller L.J., Andrawis R.I., Kurtzman S.H., Albertsen P.C., Laudone V.P.et al. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J. Urol. 157:1997;2329-2333.
14. Mazuchelli R., Montironi R., Santinelli A., Lucarini G., Pugnaloni A., Biagini G. Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients. Prostate. 45:2000;72-79.
15. Chevalier S., Defoy I., Lacoste J., Hamel L., Guy L., Bejín L.R.et al. Vascular endothelial growth factor and signaling in the prostate: more than angiogenesis. Mol. Cell. Endocrinol. 189:2002;169-179.
16. Carmena M.J., Prieto J.C. Cyclic AMP-stimulating effect of vasoactive intestinal peptide in isolated epithelial cells of rat ventral prostate. Biochim. Biophys. Acta. 463:1983;414-418.
17. Solano R.M., Carmena M.J., Carrero I., Cavallaro S., Román F., Hueso C.et al. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate. Endocrinology. 137:1996;2815-2822.
18. Juarranz M.G., Bodega G., Prieto J.C., Guijarro L.G. Neuroendocrine differentiation of the LNCaP prostate cancer cell line maintains the expression and function of VIP and PACAP receptors. Cell. Signal. 13:2001;887-894.
19. Iwata T., Ukimura O., Inaba M., Kojima M., Kumamoto K., Ozawa H.et al. Immunohistochemical studies on the distribution of nerve fibers in the human prostate with special reference to the anterior fibromuscular stroma. Prostate. 48:2001;242-247.
20. Mack D., Hacker G.W., Hauser-Kronberger C., Frick J., Dietze O. Vasoactive intestinal polypeptide (VIP) and neuropeptide tyrosine (NPY) in prostate carcinoma. Eur. J. Cancer. 33:1997;317-318.
21. Juarranz M.G., Bolaños O., Gutiérrez-Cañas I., Lerner E.A., Robberecht P., Carmena M.J.et al. Neuroendocrine differentiation of the LNCaP prostate cancer cell line maintains the expression and function of VIP and PACAP receptors. Cell. Signal. 13:2001;887-894.
22. Deeble P.D., Murphy D.J., Parsons S.J., Cox M.E. Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells. Mol. Cell. Biol. 21:2001;8471-8482.
23. 2 and vasoactive intestinal peptide increase vascular endothelial cell growth factor mRNAs in lung cancer cells. Lung Cancer. 31:2001;203-212.
24. Hu D.E., Hiley C.R., Fan T.P. Comparative studies of the angiogenic activity of vasoactive intestinal peptide, endothelins-1 and -3 and angiotensin II in a rat sponge model. Br. J. Pharmacol. 117:1996;545-551.
25. 1 receptor agonists. Peptides. 18:1997;1539-1545.
26. Gourlet P., De Neef P., Cnudde J., Waelbroeck M., Robberecht P. In vitro properties of a high affinity selective antagonist of the VIP1 receptor. Peptides. 18:1997;1555-1560.
27. Chang J.T., Chen I.H., Liao C.T., Wang H.M., Hsu Y.M., Hung K.F.et al. A reverse transcription comparative real-time PCR method for quantitative detection of angiogenic growth factors in head and neck cancer patients. Clin. Biochem. 35:2002;591-596.
28. Weidner N., Carroll P.R., Flax J., Blumenfeld W., Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am. J. Pathol. 143:1993;401-409.
29. West A.F., O'Donnell M., Charlton R.G., Neal D.E., Leung H.Y. Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer. Br. J. Cancer. 85:2001;576-583.
30. Jackson M.W., Roberts J.S., Heckford S.E., Ricciardelli C., Stahl J., Horsfall D.J.et al. A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Res. 62:2002;854-859.
31. Harper M.E., Glynne-Jones E., Goddard L., Thurston V.J., Griffiths K. Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells. Br. J. Cancer. 74:1996;910-916.
32. Akiri G., Nahari D., Finkelstein Y., Le S.Y., Elroy-Stein O., Levi B.Z. Regulation of vascular endothelial growth factor (VEGF) expression is mediated by internal initiation of translation and alternative initiation of transcription. Oncogene. 17:1998;227-236.
33. Shi Q., Le X., Abbruzzese J.L., Peng Z., Qian C.N., Tang H.et al. Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res. 61:2001;4143-4154.
34. Tong Z., Pitts G.R., You S., Foster D.N., El Halawani M.E. Vasoactive intestinal peptide stimulates turkey prolactin gene expression by increasing transcription rate and enhancing mRNA stability. J. Mol. Endocrinol. 21:1998;259-266.
35. Gloddek J., Pagotto U., Paez-Pereda M., Arzt E., Stalla G.K., Renner U. Pituitary adenylate cyclase-activating polypeptide, interleukin-6 and glucocorticoids regulate the release of vascular endothelial growth factor in pituitary folliculostellate cells. J. Endocrinol. 160:1999;483-490.
36. Moody T.W., Leyton J., Casibang M., Pisegna J., Jensen R.T. PACAP-27 tyrosine phosphorylates mitogen activated protein kinase and increases VEGF mRNAs in human lung cancer cells. Regul. Pept. 109:2002;135-140.
37. Burroughs K.D., Oh J., Barrett C., Di Augustine R.P. Phosphatidylinositol 3-kinase and mek1/2 are necessary for insulin-like growth factor-I-induced vascular endothelial growth factor synthesis in prostate epithelial cells: a role for hypoxia-inducible factor-1? Mol. Cancer Res. 1:2003;312-322.